empagliflozin
DESCRIPTION
The glucose-reducing drug empagliflozin, SGLT 2 INHIBITOR, diabetes mellitus, empagliflozin, renal glucose reabsorption, sglt2 inhibitors, treatment of type 2 diabetesTRANSCRIPT
Empagliflozin
sodium-glucose cotransporter 2 (SGLT-2)
Renal Glucose re absorption via SGLT2
The U.S. Food and Drug Administration on 1st August 2014 approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes.
It is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys
SGLT-2 inhibitors such as empagliflozin reduce blood glucose by blocking glucose reabsorption in the kidney and thereby excreting glucose (i.e., blood sugar) via the urine.
Empagliflozin is a sodium glucose cotransporter 2
(SGLT2) inhibitor that blocks the reabsorption of
glucose by the kidney, increases glucose excretion,
and lowers blood glucose levels. It has been studied
"as a stand-alone therapy and in combination with
other type 2 diabetes therapies including metformin,
sulfonylureas, pioglitazone, and insulin," according
to FDA statement announcing the approval.
This is the third SGLT2 inhibitor approved by the FDA, following the approval of
dapagliflozin (Farxiga)in January 2014
And
canagliflozin (Invokana)
in March 2013.
The sodium glucose cotransporter 2 (SGLT2) is indicated for improving glycemic control in adults with type 2 diabetes in conjunction with diet and exercise
REFERENCES :-
http://www.clinicalendocrinologynews.com/home/article/fda-approves-empagliflozin-for-adults-with-type-2-diabetes/e8e500442424cf39148f889d6fe6b16c.html
http://www.medscape.com/viewarticle/829326
http://www.nature.com/nrd/journal/v9/n7/full/nrd3180.html
http://www.google.co.in/imgres?imgurl=http%3A%2F%2Fimg.medscape.com%2Ffullsize%2Fmigrated%2Feditorial%2Fconferences%2F2008%2F15780%2Fwilding.fig1.gif&imgrefurl=http%3A%2F%2Fwww.medscape.org%2Fviewarticle%2F578176&h=435&w=547&tbnid=DoFxRsCDfjXAcM%3A&zoom=1&docid=JABzUQ1hypWRpM&ei=7v7hU_niA4WOuAS7sgE&tbm=isch&client=firefox-a&ved=0CB8QMygDMAM&iact=rc&uact=3&dur=763&page=1&start=0&ndsp=15